: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription

Articles published in Am J Hematol
Retrieve available abstracts of 359 articles:
HTML format

Single Articles

July 2021

VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
PubMed

KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
PubMed

BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
PubMed Abstract available

GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Am J Hematol. 2021;96:781-789.
PubMed Abstract available

HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
Am J Hematol. 2021;96:E259-E262.
PubMed

JENTZSCH M, Grimm J, Bill M, Brauer D, et al
Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
Am J Hematol. 2021;96:E237-E239.
PubMed

JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Am J Hematol. 2021;96:E226-E229.
PubMed

OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Am J Hematol. 2021;96:E223-E225.
PubMed

June 2021

JABBOUR E, Patel K, Jain N, Duose D, et al
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
PubMed Abstract available

LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
PubMed

MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
Ruxolitinib for refractory large granular lymphocyte leukemia.
Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
PubMed

HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
Am J Hematol. 2021;96:E187-E189.
PubMed

May 2021

AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
PubMed Abstract available

PICIOCCHI A, Messina M, Elia L, Vitale A, et al
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
PubMed

ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
PubMed

MOULIN C, Guillemin F, Remen T, Bouclet F, et al
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
PubMed

JAIN N, Maiti A, Ravandi F, Konopleva M, et al
Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
PubMed Abstract available

MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
PubMed

HALL KH, Brooks A, Waller EK
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
PubMed

MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Am J Hematol. 2021;96:E168-E171.
PubMed

OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
Am J Hematol. 2021;96:E140-E143.
PubMed

April 2021

KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
PubMed Abstract available

YILMAZ M, Daver N, Borthakur G, Kadia T, et al
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
PubMed

MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
PubMed

JAMY O, Godby R, Sarmad R, Costa LJ, et al
Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
PubMed

PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
PubMed Abstract available

APEL A, Moshe Y, Ofran Y, Gural A, et al
Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
PubMed Abstract available

DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
PubMed Abstract available

GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
Young platelet millionaires with essential thrombocythemia.
Am J Hematol. 2021;96:E93-E95.
PubMed

PARDANANI A
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Am J Hematol. 2021;96:508-525.
PubMed Abstract available

March 2021

SHORT NJ, Konopleva M, Kadia T, Kebriaei P, et al
An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Am J Hematol. 2021 Mar 29. doi: 10.1002/ajh.26175.
PubMed

AUDIL HY, Hampel PJ, Van Dyke DL, Achenbach SJ, et al
The Prognostic Significance of del6q23 in Chronic Lymphocytic Leukemia.
Am J Hematol. 2021 Mar 22. doi: 10.1002/ajh.26168.
PubMed

LIU S, Deng B, Yin Z, Lin Y, et al
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Am J Hematol. 2021 Mar 16. doi: 10.1002/ajh.26160.
PubMed Abstract available

SALHOTRA A, Aribi A, Ngo D, Zhang J, et al
Outcome of secondary Acute Myeloid Leukemia treated with Hypomethylating agent plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin-Cytarabine (CPX-351).
Am J Hematol. 2021 Mar 14. doi: 10.1002/ajh.26157.
PubMed

SASAKI K, Jabbour E, Short NJ, Jain N, et al
Acute Lymphoblastic Leukemia: A Population- based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980-2017.
Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26156.
PubMed Abstract available

BALL BJ, Hsu M, Devlin SM, Arcila M, et al
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
Am J Hematol. 2021 Mar 1. doi: 10.1002/ajh.26146.
PubMed

WILHELMSSON M, Jahnukainen K, Winiarski J, Abrahamsson J, et al
Hospitalizations in long-term survivors of childhood AML treated with allogeneic HCT-An Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.
Am J Hematol. 2021;96:E74-E77.
PubMed

FERNANDES F, Ramalho R, Barreira R, Silveira M, et al
Large granular lymphocytosis induced by dasatinib.
Am J Hematol. 2021;96:395-396.
PubMed

February 2021

CHATZIDIMITRIOU C, Pappa V, Lakiotaki E, Plata E, et al
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26145.
PubMed

MORITA K, Jain N, Kantarjian H, Takahashi K, et al
Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
PubMed Abstract available

MOU T, Pawitan Y, Stahl M, Vesterlund M, et al
The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.
Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26141.
PubMed Abstract available

FATHI AT, Stein EM, DiNardo CD, Levis MJ, et al
Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26142.
PubMed Abstract available

DAVER N, Salhotra A, Brandwein JM, Podoltsev NA, et al
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
Am J Hematol. 2021 Feb 22. doi: 10.1002/ajh.26136.
PubMed

VENUGOPAL S, Maiti A, DiNardo CD, Loghavi S, et al
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26122.
PubMed

WANG S, Wang X, Ye C, Cheng H, et al
Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26123.
PubMed

BEGNA KH, Gangat N, Al-Kali A, Litzow MR, et al
Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive vs HMA +/- venetoclax chemotherapy.
Am J Hematol. 2021 Feb 2. doi: 10.1002/ajh.26112.
PubMed

ZHENG H, Mineishi S, Claxton D, Zhu J, et al
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
Am J Hematol. 2021;96:E46-E50.
PubMed

January 2021

RICHARDSON DR, Swoboda DM, Moore DT, Johnson SM, et al
Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia.
Am J Hematol. 2021 Jan 27. doi: 10.1002/ajh.26110.
PubMed Abstract available

HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26107.
PubMed

JONAS BA, Fisch SC, Rosenberg AS, Hoeg RT, et al
Phase I Study of Escalating Doses of Carfilzomib with HyperCVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26105.
PubMed

December 2020

BROWN JR, Walker SR, Heppler LN, Tyekucheva S, et al
Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses.
Am J Hematol. 2020 Dec 29. doi: 10.1002/ajh.26084.
PubMed

CORTES JE, Mehta P
Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia.
Am J Hematol. 2020 Dec 23. doi: 10.1002/ajh.26079.
PubMed Abstract available

WANG HP, Zhou YL, Huang X, Zhang Y, et al
CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
Am J Hematol. 2020 Dec 11. doi: 10.1002/ajh.26069.
PubMed Abstract available

TESTI AM, Canichella M, Vitale A, Piciocchi A, et al
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase ii pediatric-like gimema lal-1308 trial.
Am J Hematol. 2020 Dec 7. doi: 10.1002/ajh.26066.
PubMed Abstract available

KOLLER PB, Zhang H, Kantarjian H, Jabbour E, et al
GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis.
Am J Hematol. 2020 Dec 4. doi: 10.1002/ajh.26065.
PubMed

MAITI A, Qiao W, Sasaki K, Ravandi F, et al
Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality.
Am J Hematol. 2020 Dec 2. doi: 10.1002/ajh.26061.
PubMed Abstract available

DIAO S, Nichols ED, DiNardo C, Konopleva M, et al
Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax.
Am J Hematol. 2020 Dec 1. doi: 10.1002/ajh.26060.
PubMed

PATEL S, Nayernama A, Jones SC, de Claro RA, et al
BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Am J Hematol. 2020;95:E332-E335.
PubMed

SASAKI K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, et al
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Am J Hematol. 2020;95:E326-E329.
PubMed

OFORI K, Soderquist CR, Murty VV, Park D, et al
The clinical and pathological features of plasma cell myeloma post solid organ transplantation.
Am J Hematol. 2020;95:1531-1541.
PubMed Abstract available

November 2020

ARSLAN S, Zhang J, Dhakal P, Moran J, et al
Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia.
Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057.
PubMed

SASAKI K, Jabbour EJ, Ravandi F, Konopleva M, et al
The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes.
Am J Hematol. 2020 Nov 12. doi: 10.1002/ajh.26047.
PubMed Abstract available

MONTALBAN-BRAVO G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, et al
Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia.
Am J Hematol. 2020 Nov 6. doi: 10.1002/ajh.26044.
PubMed

GARCIA-MANERO G, Chien KS, Montalban-Bravo G
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Am J Hematol. 2020;95:1399-1420.
PubMed Abstract available

MANNELLI F, Gianfaldoni G, Bencini S, Piccini M, et al
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
Am J Hematol. 2020;95:1304-1313.
PubMed Abstract available

October 2020

POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
PubMed Abstract available

BRANDWEIN JM, Hallett D, Karkhaneh M, Zhu N, et al
An Evaluation of No-Treatment Decisions in Patients with Newly Diagnosed Acute Myeloid Leukemia.
Am J Hematol. 2020 Oct 6. doi: 10.1002/ajh.26012.
PubMed

RAUTENBERG C, Germing U, Stepanow S, Lauseker M, et al
Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia.
Am J Hematol. 2020 Oct 5. doi: 10.1002/ajh.26013.
PubMed

Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
Am J Hematol. 2020;95 Suppl 1:S3-S38.
PubMed

September 2020

POIANI M, Labopin M, Battipaglia G, Beelen DW, et al
The impact of cytogenetic risk on the outcomes of Allogeneic Hematopoietic Cell Transplantation in patients with relapsed/refractory acute myeloid leukemia: on behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.
Am J Hematol. 2020 Sep 17. doi: 10.1002/ajh.26000.
PubMed Abstract available

MARZOLLO A, Maestrini G, La Starza R, Elia L, et al
A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell Acute Lymphoblastic Leukemia.
Am J Hematol. 2020 Sep 16. doi: 10.1002/ajh.25998.
PubMed

CHO BS, Min GJ, Park S, Park SS, et al
Haploidentical versus matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study.
Am J Hematol. 2020 Sep 9. doi: 10.1002/ajh.25993.
PubMed Abstract available

BARON F, Labopin M, Ruggeri A, Sierra J, et al
Impact of detectable measurable residual disease on umbilical cord blood transplantation.
Am J Hematol. 2020;95:1057-1065.
PubMed Abstract available

SMITH CJ, Kluck LA, Ruan GJ, Ashrani AA, et al
The differential diagnosis of basophilia in patients undergoing BCR-ABL testing.
Am J Hematol. 2020;95:E216-E217.
PubMed

MARGOLSKEE E, Pillai V
Loss of surface CD3 expression in allogeneic CAR T-cells.
Am J Hematol. 2020;95:1115-1116.
PubMed

August 2020

PAGNANO KBB, Lopes ABP, Miranda EC, Delamain MT, et al
Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia with Deep Molecular Response.
Am J Hematol. 2020 Aug 30. doi: 10.1002/ajh.25986.
PubMed

VAN ELSSEN CHMJ, Ciurea SO
NK Cell Alloreactivity in Acute Myeloid Leukemia in the Post-transplant Cyclophosphamide Era.
Am J Hematol. 2020 Aug 28. doi: 10.1002/ajh.25983.
PubMed Abstract available

MORSIA E, McCullough K, Joshi M, Cook J, et al
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25978.
PubMed Abstract available

ESTEY EH
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25975.
PubMed

SANDBERG Y, Verhoeven GT, Weerkamp F, Broyl A, et al
Primary plasma cell leukemia mimicking a Pancoast tumor.
Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25977.
PubMed

PLEYER C, Tian X, Rampertaap S, Mu R, et al
A Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25968.
PubMed

CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
PubMed Abstract available

SAYGIN C, Larkin K, Blachly JS, Orwick S, et al
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25958.
PubMed Abstract available

JONDREVILLE L, Krzisch D, Chapiro E, Nguyen-Khac F, et al
The complex karyotype and chronic lymphocytic leukemia. A review of the literature.
Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25956.
PubMed Abstract available

JENG MY, Dutta R, Tan IT, Zhang TY, et al
Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25949.
PubMed

KOFFMAN B, Mato A, Byrd JC, Danilov A, et al
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.
Am J Hematol. 2020;95:E199-E203.
PubMed

PATNAIK MM, Lasho T, Padron E, McCullough K, et al
Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
Am J Hematol. 2020;95:E203-E208.
PubMed

July 2020

BORTHAKUR G, Zeng Z, Cortes JE, Chen HC, et al
Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25943.
PubMed Abstract available

ABAZA Y, Kantarjian H, Alwash Y, Borthakur G, et al
Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia.
Am J Hematol. 2020 Jul 18. doi: 10.1002/ajh.25939.
PubMed Abstract available

DHOLARIA B, Labopin M, Angelucci E, Ciceri F, et al
Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia.
Am J Hematol. 2020 Jul 13. doi: 10.1002/ajh.25934.
PubMed Abstract available

ALDOSS I, Zhang J, Mei M, Al Malki MM, et al
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929.
PubMed Abstract available

COLADO A, Marin Franco JL, Elias EE, Amondarain M, et al
Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
Am J Hematol. 2020;95:E174-E178.
PubMed

KIM GYG, Burns J, Freyer CW, Hamilton KW, et al
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
Am J Hematol. 2020;95:792-798.
PubMed Abstract available

June 2020

BOCK AM, Pollyea DA
Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.
Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25916.
PubMed

DAGA S, Rosenberger A, Kashofer K, Heitzer E, et al
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25918.
PubMed Abstract available

OHANIAN M, Kantarjian HM, Shoukier M, Dellasala S, et al
The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.
Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25907.
PubMed Abstract available

IURLO A, Cattaneo D, Malato A, Accurso V, et al
Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis.
Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25908.
PubMed

RUAN GJ, Smith CJ, Day C, Harmsen WS, et al
A Population-based Study of Chronic Eosinophilic Leukemia-Not Otherwise Specified in the United States.
Am J Hematol. 2020 Jun 13. doi: 10.1002/ajh.25906.
PubMed

HASTINGS A, Apperley JF, Nadal-Melsio E, Brown L, et al
Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25903.
PubMed

JAIN P, Wang XI
Carcinocythemia - cancer cell leukemia.
Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25902.
PubMed

SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.
PubMed

SUNG AD, Jauhari S, Siamakpour-Reihani S, Rao AV, et al
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
Am J Hematol. 2020;95:662-671.
PubMed Abstract available

PATEL SS, Weinberg OK
Diagnostic workup of acute leukemias of ambiguous lineage.
Am J Hematol. 2020;95:718-722.
PubMed Abstract available

May 2020

QASRAWI A, Ramlal R, Munker R, Hildebrandt GC, et al
Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome.
Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25873.
PubMed Abstract available

BYRNE M, Danielson N, Sengsayadeth S, Rasche A, et al
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Am J Hematol. 2020 May 10. doi: 10.1002/ajh.25859.
PubMed Abstract available

AITKEN MJL, Benton CB, Wang F, Zhang J, et al
33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient.
Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25850.
PubMed

April 2020

SHORT NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, et al
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
Am J Hematol. 2020 Apr 30. doi: 10.1002/ajh.25854.
PubMed

CADENAS FL, Bua BR, Campelo MD, Rieu JB, et al
A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25842.
PubMed

CHRISTIAN S, Arain S, Patel P, Khan I, et al
A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25838.
PubMed Abstract available

MAFFINI E, Labopin M, Blaise D, Ciceri F, et al
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the Euro
Am J Hematol. 2020 Apr 17. doi: 10.1002/ajh.25826.
PubMed Abstract available

KLEINSTERN G, O'Brien DR, Li X, Tian S, et al
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25831.
PubMed Abstract available

GIARDINO S, Peffault de Latour R, Aljurf M, Eikema DJ, et al
Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group.
Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25810.
PubMed Abstract available

ROGERS HJ, Wang X, Xie Y, Davis AR, et al
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a Bone Marrow Pathology Group study.
Am J Hematol. 2020 Apr 6. doi: 10.1002/ajh.25814.
PubMed Abstract available

MORSIA E, Reichard K, Pardanani A, Tefferi A, et al
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25811.
PubMed

ZHU HH, Yang MC, Wang F, Lou YJ, et al
Identification of a novel NUP98-RARA fusion transcript as the 14(th) variant of acute promyelocytic leukemia.
Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25807.
PubMed

LOSCOCCO GG, Mannelli F, Mannelli L, Vergoni F, et al
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease.
Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.
PubMed

KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
PubMed

JABBOUR E, Kantarjian H
Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring.
Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25792.
PubMed Abstract available

OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
A heavy metal baseline score predicts outcome in acute myeloid leukemia.
Am J Hematol. 2020;95:422-434.
PubMed Abstract available

COLTRO G, Antelo G, Lasho TL, Finke CM, et al
Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
Am J Hematol. 2020;95:E86-E89.
PubMed

March 2020

BARON F, Efficace F, Cannella L, Muus P, et al
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study.
Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25795.
PubMed Abstract available

SASAKI K, Kantarjian H, Wierda W, Ravandi F, et al
Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784.
PubMed Abstract available

LIU H, Miao Y, Ferrajoli A, Tang G, et al
Leukemic Phase of Richter transformation: A Mimic of Acute Myeloid Leukemia that Responded to Ibrutinib Monotherapy.
Am J Hematol. 2020 Mar 12. doi: 10.1002/ajh.25782.
PubMed Abstract available

HU KX, Du X, Guo M, Yu CL, et al
Comparative study of micro-transplantation from HLA fully mismatched unrelated and partly matched related donors in acute myeloid leukemia.
Am J Hematol. 2020 Mar 10. doi: 10.1002/ajh.25780.
PubMed Abstract available

EVANS LA, Jevremovic D, Nandakumar B, Dispenzieri A, et al
Utilizing Multiparametric Flow Cytometry in the Diagnosis of Patients with Primary Plasma Cell Leukemia.
Am J Hematol. 2020 Mar 4. doi: 10.1002/ajh.25773.
PubMed Abstract available

ZHAO Y, Mullenbach B, Wang E
Isolated cerebrospinal fluid relapse of acute myeloid leukemia status post stem cell transplant: a neuroleukemiosis manifesting as polyneuropathy.
Am J Hematol. 2020 Mar 2. doi: 10.1002/ajh.25772.
PubMed

GARCIA JS, Bhatt S, Fell G, Sperling AS, et al
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Am J Hematol. 2020;95:245-250.
PubMed Abstract available

February 2020

MONTALBAN-BRAVO G, Kanagal-Shamanna R, Class CA, Sasaki K, et al
Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy.
Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769.
PubMed

HERISHANU Y, Shaulov A, Fineman R, BasiC-Kinda S, et al
Frontline treatment with the combination obinutuzumab+/-chlorambucil for chronic lymphocytic leukemia outside clinical trials: results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol. 2020 Feb 25. doi: 10.1002/ajh.25766.
PubMed Abstract available

STERLING C, Webster J
"Harnessing the Immune System After Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia".
Am J Hematol. 2020 Feb 5. doi: 10.1002/ajh.25750.
PubMed Abstract available

January 2020

MOORE J, Baran AM, Meacham PJ, Evans AG, et al
Initial treatment of B-cell Prolymphocytic Leukemia with Ibrutinib.
Am J Hematol. 2020 Jan 17. doi: 10.1002/ajh.25733.
PubMed

ANAGNOSTOU T, Knudson RA, Pearce KE, Meyer RG, et al
Clinical Utility of Fluorescence In Situ Hybridization-based Diagnosis of BCR-ABL1 like (Philadelphia Chromosome like) B-Acute Lymphoblastic Leukemia.
Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25729.
PubMed

ZHU HH, Qian JJ, Sun WJ, You LS, et al
Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
Am J Hematol. 2020 Jan 7. doi: 10.1002/ajh.25719.
PubMed

WILLIAMS AM, Baran AM, Schaffer M, Bushart J, et al
Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Am J Hematol. 2020;95:E16-E18.
PubMed

December 2019

POIRE X, Labopin M, Polge E, Volin L, et al
The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.
Am J Hematol. 2019 Dec 26. doi: 10.1002/ajh.25714.
PubMed Abstract available

HAMPEL PJ, Call TG, Ding W, Muchtar E, et al
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: combination therapy to prevent ibrutinib flare.
Am J Hematol. 2019 Dec 1. doi: 10.1002/ajh.25690.
PubMed

MERLI M, Passamonti F
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
Am J Hematol. 2019;94:1303-1305.
PubMed

November 2019

SZUBER N, Elliott M, Tefferi A
Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.
Am J Hematol. 2019 Nov 25. doi: 10.1002/ajh.25688.
PubMed Abstract available

ZHANG Z, Jiang M, Borthakur G, Luan S, et al
Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
Am J Hematol. 2019 Nov 25. doi: 10.1002/ajh.25689.
PubMed

PATNAIK MM, Tefferi A
Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management.
Am J Hematol. 2019 Nov 17. doi: 10.1002/ajh.25684.
PubMed Abstract available

MATTSSON M, Sandin F, Kimby E, Hoglund M, et al
Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise; a nationwide population-based study.
Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25681.
PubMed

NALGHRANYAN S, Singh AP, Schinke C
The Combination of Venetoclax, Daratumumab and Dexamethasone for the treatment of refractory primary plasma cell leukemia.
Am J Hematol. 2019 Nov 10. doi: 10.1002/ajh.25676.
PubMed

YILMAZ M, Kantarjian H, Wang X, Khoury JD, et al
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Am J Hematol. 2019 Nov 3. doi: 10.1002/ajh.25671.
PubMed Abstract available

KOWALCZYK JR, Zawitkowska J, Lejman M, Drabko K, et al
Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
Am J Hematol. 2019;94:E307-E310.
PubMed

MOLICA M, Breccia M, Foa R, Jabbour E, et al
Maintenance therapy in AML: The past, the present and the future.
Am J Hematol. 2019;94:1254-1265.
PubMed Abstract available

NISHIWAKI S, Mizuta S, Ohashi K, Fukuda T, et al
Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease.
Am J Hematol. 2019;94:E301-E305.
PubMed

AMBINDER AJ, Hambley B, Shanbhag S, Merrill SA, et al
Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Am J Hematol. 2019;94:E296-E299.
PubMed

PENTHER D, Etancelin P, Lusina D, Bidet A, et al
Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features.
Am J Hematol. 2019;94:E285-E288.
PubMed

HAN X, Wang C, Zhou J
Chimeric antigen receptor T (CAR-T) cells present with reactive and pleomorphic morphology in bone marrow.
Am J Hematol. 2019;94:1297-1298.
PubMed

October 2019

KRAKOW EF, Gyurkocza B, Storer BE, Chauncey TR, et al
Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.
Am J Hematol. 2019 Oct 22. doi: 10.1002/ajh.25665.
PubMed Abstract available

PEREZ-MARTINEZ A, Ferreras C, Pascual A, Gonzalez-Vicent M, et al
Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON) and the Spanish Grupo for Hematopoietic Transplantation (G
Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25661.
PubMed Abstract available

SROUR SA, Saliba RM, Bittencourt MC, Ramos Perez JM, et al
Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.
Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25647.
PubMed Abstract available

DALLE IA, Kantarjian HM, Short NJ, Konopleva M, et al
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25648.
PubMed Abstract available

MAITRE E, Cornet E, Troussard X
Hairy cell leukemia 2020: Update on diagnosis, risk-stratification, and treatment.
Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25653.
PubMed Abstract available

LUBOWIECKI M, Siow W, Eagleton H, Bain BJ, et al
Large granular lymphocytic leukemia as a cause of pancytopenia.
Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25650.
PubMed

OFRAN Y, Hayun M, Leiba R, Zuckerman T, et al
Bone marrow blast elimination by the fifth day of 7+3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651.
PubMed

September 2019

MUNIR T, Brown JR, O'Brien S, Barrientos JC, et al
Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638.
PubMed Abstract available

FLINN IW, Cherry MA, Maris MB, Matous JV, et al
Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia.
Am J Hematol. 2019 Sep 6. doi: 10.1002/ajh.25634.
PubMed Abstract available

TU S, Huang R, Guo Z, Deng L, et al
Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CRES or severe CRS.
Am J Hematol. 2019 Sep 5. doi: 10.1002/ajh.25630.
PubMed

MANOHAR S, Bansal A, Wanchoo R, Sakhiya V, et al
Ibrutinib induced acute tubular injury: A case series and review of the literature.
Am J Hematol. 2019;94:E223-E225.
PubMed

August 2019

LAUSEKER M, Bachl K, Turkina A, Faber E, et al
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Am J Hematol. 2019 Aug 27. doi: 10.1002/ajh.25628.
PubMed Abstract available

TOMLINSON BK, Tuscano JM, Abedi M, Welborn J, et al
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25605.
PubMed

PATEL SS, Pinkus GS, Ritterhouse LL, Segal JP, et al
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
Am J Hematol. 2019;94:921-928.
PubMed Abstract available

DUNLAP JB, Leonard J, Rosenberg M, Cook R, et al
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Am J Hematol. 2019;94:913-920.
PubMed Abstract available

JUST VINHOLT P, Hojrup Knudsen G, Sperling S, Frederiksen H, et al
Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia.
Am J Hematol. 2019;94:891-901.
PubMed Abstract available

July 2019

IURLO A, Bucelli C, Cattaneo D, Levati GV, et al
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.
Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25596.
PubMed

HALLEK M
Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment.
Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25595.
PubMed Abstract available

MOYERS JT, Liu LW, Ossowski S, Goddard L, et al
A Rash in a Hairy Situation: Leukocytoclastic Vasculitis at Presentation of Hairy Cell Leukemia.
Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25597.
PubMed

CUNNINGHAM I, Hamele-Bena D, Guo Y, Shiomi T, et al
Extramedullary Leukemia Behaving as Solid Cancer: Clinical, Histologic, and Genetic Clues to Chemoresistance in Organ Sites.
Am J Hematol. 2019 Jul 28. doi: 10.1002/ajh.25594.
PubMed Abstract available

JIANG H, Li C, Yin P, Guo T, et al
Anti-CD19 CAR-T Therapy Bridging to Allo-HSCT for Relapsed/refractory B-cell Acute Lymphoblastic Leukemia: An Open-Label Pragmatic Clinical Trial.
Am J Hematol. 2019 Jul 18. doi: 10.1002/ajh.25582.
PubMed Abstract available

IACCARINO L, Ottone T, Alfonso V, Cicconi L, et al
Mutational landscape of patients with Acute Promyelocytic Leukemia at diagnosis and relapse.
Am J Hematol. 2019 Jul 10. doi: 10.1002/ajh.25573.
PubMed Abstract available

GONG Z, Xu ML, Chen M, Cui W, et al
Philadelphia chromosome-negative acute leukemia in chronic myeloid leukemia.
Am J Hematol. 2019 Jul 4. doi: 10.1002/ajh.25571.
PubMed

ALDOSS I, Yang D, Pillai R, Sanchez JF, et al
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Am J Hematol. 2019 Jul 1. doi: 10.1002/ajh.25567.
PubMed

STRATI P, Garcia-Manero G, Zhao C, Kadia T, et al
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.
Am J Hematol. 2019;94:E188-E190.
PubMed

KOUTSILIERI S, Caudle KE, Alzghari SK, Monte AA, et al
Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango.
Am J Hematol. 2019;94:737-740.
PubMed

QUINQUENEL A, Godet S, Dartigeas C, Ysebaert L, et al
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Am J Hematol. 2019;94:E183-E185.
PubMed

June 2019

AL-SAWAF O, Bazeos A, Robrecht S, Bahlo J, et al
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol. 2019 Jun 20. doi: 10.1002/ajh.25561.
PubMed Abstract available

YALNIZ F, Abou Dalle I, Kantarjian H, Borthakur G, et al
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553.
PubMed Abstract available

POLLYEA DA
Acute Myeloid Leukemia Drug Development in the Post-Venetoclax Era.
Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25556.
PubMed

May 2019

PRESS RD, Eickelberg G, Froman A, Yang F, et al
NGS-Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse.
Am J Hematol. 2019 May 23. doi: 10.1002/ajh.25514.
PubMed Abstract available

PICHLER H, Lawitschka A, Glogova E, Willasch AM, et al
Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia - A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP.
Am J Hematol. 2019 May 16. doi: 10.1002/ajh.25511.
PubMed Abstract available

O'BRIEN SM, Byrd JC, Hillmen P, Coutre S, et al
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol. 2019;94:554-562.
PubMed Abstract available

ZHAO XS, Liu YR, Xu LP, Wang Y, et al
Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.
Am J Hematol. 2019;94:512-521.
PubMed Abstract available

April 2019

COSTON T, Pophali P, Vallapureddy R, Lasho TL, et al
Suboptimal Response Rates to Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia; a Single Institutional Study of 121 Patients.
Am J Hematol. 2019 Apr 9. doi: 10.1002/ajh.25488.
PubMed Abstract available

MEDEIROS BC, Chan SM, Daver NG, Jonas BA, et al
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
Am J Hematol. 2019 Apr 3. doi: 10.1002/ajh.25484.
PubMed Abstract available

HAMLIN PA, Flinn IW, Wagner-Johnston N, Burger JA, et al
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Am J Hematol. 2019;94:E90-E93.
PubMed

March 2019

LI N, Wang SA, Lin P, Jabbour E, et al
Relapsed B-Acute Lymphoblastic Leukemia with Aberrant Myeloperoxidase Expression Following CAR T-cell Therapy: A Diagnostic Challenge.
Am J Hematol. 2019 Mar 27. doi: 10.1002/ajh.25478.
PubMed

BOHN JP, Pircher A, Wanner D, Vill D, et al
Low-dose vemurafenib in hairy cell leukemia patients with active infection.
Am J Hematol. 2019 Mar 27. doi: 10.1002/ajh.25474.
PubMed

LEUNG GMK, Zhang C, Ng NKL, Yang N, et al
Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
Am J Hematol. 2019 Mar 22. doi: 10.1002/ajh.25469.
PubMed Abstract available

BHATT VR, Shostrom V, Armitage JO, Gundabolu K, et al
Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.
Am J Hematol. 2019 Mar 18. doi: 10.1002/ajh.25464.
PubMed

BAIR SM, Porter DL
Accelerating CAR therapy in CLL: The development and challenges of CAR T cell therapy for chronic lymphocytic leukemia.
Am J Hematol. 2019 Mar 12. doi: 10.1002/ajh.25457.
PubMed Abstract available

ABBAS HA, Ravandi F, Loghavi S, Patel KP, et al
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML.
Am J Hematol. 2019 Mar 5. doi: 10.1002/ajh.25454.
PubMed

FURUTANI E, Newburger PE, Shimamura A
Neutropenia in the age of genetic testing: Advances and challenges.
Am J Hematol. 2019;94:384-393.
PubMed Abstract available

CORTES J, Rea D, Lipton JH
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Am J Hematol. 2019;94:346-357.
PubMed Abstract available

February 2019

FREY NV
CAR T cells for Acute Lymphoblastic Leukemia.
Am J Hematol. 2019 Feb 19. doi: 10.1002/ajh.25442.
PubMed Abstract available

SAWAYAMA Y, Itonaga H, Fukushima T, Nakano N, et al
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25438.
PubMed

CALDWELL I, Ruskova A, Royle G, Liang J, et al
Pure erythroid leukemia: The value of E-cadherin in making the diagnosis.
Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25437.
PubMed

SUI JN, Chen QS, Zhang YX, Sheng Y, et al
Identifying Leukemia-Associated Immunophenotype-based Individualized Minimal Residual Disease in Acute Myeloid Leukemia and its Prognostic Significance.
Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25431.
PubMed Abstract available

January 2019

QASIM W
Allogeneic CAR T cell therapies for leukemia - R1.
Am J Hematol. 2019 Jan 11. doi: 10.1002/ajh.25399.
PubMed Abstract available

JABBOUR E, Advani AS, Stelljes M, Stock W, et al
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Am J Hematol. 2019 Jan 8. doi: 10.1002/ajh.25394.
PubMed Abstract available

SZARZYNSKA-ZAWADZKA B, Kunz J, Sedek L, Kosmalska M, et al
PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
Am J Hematol. 2019 Jan 7. doi: 10.1002/ajh.25396.
PubMed

EL CHAER F, Ali OM, Sausville EA, Law JY, et al
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
Am J Hematol. 2019;94:E7-E8.
PubMed

December 2018

LEE CJ, Labopin M, Beelen D, Finke J, et al
Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.
Am J Hematol. 2018 Dec 30. doi: 10.1002/ajh.25395.
PubMed Abstract available

FANG H, Reichard KK, Rabe KG, Hanson CA, et al
IGH translocations in chronic lymphocytic leukemia (CLL): clinicopathologic features and clinical outcomes.
Am J Hematol. 2018 Dec 21. doi: 10.1002/ajh.25385.
PubMed Abstract available

ANAND K, Kumar P, Pingali SR, Pati D, et al
Acute Myeloid Leukemia with Eosinophilia (AML-M4Eo) after Cyclin Dependent Kinases 4/6 Inhibitor Treatment Due to Underlying Clonal Hematopoiesis of Indeterminate Potential (CHIP).
Am J Hematol. 2018 Dec 21. doi: 10.1002/ajh.25380.
PubMed

November 2018

MEI M, Aldoss I, Marcucci G, Pullarkat V, et al
Hypomethylating Agents in combination with Venetoclax for Acute Myeloid Leukemia: Update on Clinical trial data and Practical Considerations for use.
Am J Hematol. 2018 Nov 30. doi: 10.1002/ajh.25369.
PubMed Abstract available

POIRE X, Labopin M, Polge E, Blaise D, et al
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.
Am J Hematol. 2018 Nov 19. doi: 10.1002/ajh.25355.
PubMed Abstract available

ANDREANI G, Dragani M, Serra A, Nicoli P, et al
Venetoclax plus Decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25352.
PubMed

SHANMUGAM V, Dorfman DM
Acute myeloid leukemia with minimal differentiation (AML M0) mimicking acute lymphoblastic leukemia.
Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25354.
PubMed

SAINI N, Cerny J, Furtado V, Desmond A, et al
Elderly do benefit from induction chemotherapy: High dose mitoxantrone based ("5+1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia.
Am J Hematol. 2018 Nov 12. doi: 10.1002/ajh.25347.
PubMed Abstract available

SHORT NJ, Jabbour E, Albitar M, de Lima M, et al
Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts.
Am J Hematol. 2018 Nov 5. doi: 10.1002/ajh.25338.
PubMed Abstract available

October 2018

BAHASHWAN S, Molucon-Chabrot C, Hermet E, Ravinet A, et al
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25332.
PubMed

LITZOW MR, Wang XV, Carroll MP, Karp JE, et al
A Randomized Trial of Three Novel Regimens for Recurrent Acute Myeloid Leukemia Demonstrates the Continuing Challenge of Treating this Difficult Disease.
Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25333.
PubMed Abstract available

JELINEK T, Mihalyova J, Kascak M, Duras J, et al
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14].
Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25331.
PubMed

KONUMA T, Harada K, Yamasaki S, Mizuno S, et al
Upfront allogeneic HCT vs remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: a propensity score matched analysis.
Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25336.
PubMed Abstract available

LOEFF FC, Rijs K, van Egmond EHM, Zoutman WH, et al
Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25337.
PubMed Abstract available

RENAUD L, Nibourel O, Marceau-Renaut A, Gruson B, et al
Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatory.
Am J Hematol. 2018 Oct 25. doi: 10.1002/ajh.25328.
PubMed

SHORT NJ, Jabbour E, Naqvi K, Patel A, et al
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25318.
PubMed Abstract available

HEHLMANN R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, et al
Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY.
Am J Hematol. 2018 Oct 5. doi: 10.1002/ajh.25306.
PubMed Abstract available

ESTEY EH
Acute myeloid leukemia: 2019 update on risk-stratification and management.
Am J Hematol. 2018;93:1267-1291.
PubMed Abstract available

September 2018

BEGNA KH, Ali W, Gangat N, Elliott MA, et al
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.
Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25290.
PubMed

CHRISTOPEIT M, Labopin M, Gorin NC, Saraceni F, et al
Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Am J Hematol. 2018 Sep 14. doi: 10.1002/ajh.25285.
PubMed Abstract available

JACOBY E, Bielorai B, Avigdor A, Itzhaki O, et al
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Am J Hematol. 2018 Sep 6. doi: 10.1002/ajh.25274.
PubMed Abstract available

August 2018

YANG MH, Wan WQ, Luo JS, Zheng MC, et al
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study.
Am J Hematol. 2018 Aug 30. doi: 10.1002/ajh.25271.
PubMed Abstract available

JAIN P, Kanagal-Shamanna R, Konoplev SN, Zuo Z, et al
Biclonal IGHV-4-34 variant hairy cell leukemia and CLL - successful treatment with ibrutinib and venetoclax.
Am J Hematol. 2018 Aug 28. doi: 10.1002/ajh.25264.
PubMed

HOW J, Vij KR, Ebadi M, DeFor TE, et al
Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Am J Hematol. 2018 Aug 24. doi: 10.1002/ajh.25262.
PubMed

ROBAK T, Burger JA, Tedeschi A, Barr PM, et al
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies.
Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259.
PubMed Abstract available

ASSI R, Gur HD, Loghavi S, Konoplev SN, et al
P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival.
Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25255.
PubMed Abstract available

MI X, Griffin G, Lee W, Patel S, et al
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.
Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25256.
PubMed Abstract available

CUNNINGHAM I, Worthley D, Gastroenterologist C
LEUKEMIA IN GI ORGANS AS CAUSE OF TREATMENT FAILURE: 378 CASES ANALYZED.
Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25250.
PubMed Abstract available

HO G, Li Q, Brunson A, Jonas BA, et al
Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia treated in California.
Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25252.
PubMed

POPHALI P, Horna P, Lasho TL, Finke CM, et al
Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of 39 patients.
Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25246.
PubMed Abstract available

XIA D, Hsi ED, Cin PD, Hasserjian RP, et al
Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.
Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25249.
PubMed

O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
PubMed Abstract available

ABAZA Y, Cortes J, Ravandi F, Kadia T, et al
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25240.
PubMed Abstract available

ELLIOTT MA, Tefferi A
Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
Am J Hematol. 2018;93:578-587.
PubMed Abstract available

July 2018

SIEGEL SE, Advani A, Seibel N, Muffly L, et al
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
PubMed Abstract available

ROSENTHAL J, Naqvi AS, Luo M, Wertheim G, et al
Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25235.
PubMed Abstract available

SARACENI F, Beohou E, Labopin M, Arcese W, et al
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25225.
PubMed Abstract available

OHANIAN M, Garcia-Manero G, Levis M, Jabbour E, et al
Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML).
Am J Hematol. 2018 Jul 20. doi: 10.1002/ajh.25198.
PubMed Abstract available

NORWOOD J, Pastoret C, Luycx O, Le Coz MF, et al
Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25217.
PubMed

FATHI AT, Hobbs G, Dey BR, Chen YB, et al
Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25218.
PubMed

MORABITO F, Shanafelt TD, Gentile M, Reda G, et al
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases.
Am J Hematol. 2018 Jul 9. doi: 10.1002/ajh.25206.
PubMed

GILLEECE MH, Labopin M, Yakoub-Agha I, Volin L, et al
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Part
Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25211.
PubMed Abstract available

June 2018

PATNAIK MM, Tefferi A
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
Am J Hematol. 2018;93:824-840.
PubMed Abstract available

May 2018

CHYLA B, Daver N, Doyle K, McKeegan E, et al
Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia.
Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25146.
PubMed

BACIGALUPO A, Van Lint MT, Sica S, Laurenti L, et al
High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.
Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25131.
PubMed

April 2018

SIEGELE BJ, Nardi V
Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
PubMed Abstract available

CUI L, Li ZG, Chai YH, Yu J, et al
Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25124.
PubMed Abstract available

GORIN NC, Labopin M, Blaise D, Dumas PY, et al
Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia: Better Outcomes with Busulfan and Melphalan compared with Busulfan and Cyclophosphamide in high Risk Patients autografted in First Complete Re
Am J Hematol. 2018 Apr 12. doi: 10.1002/ajh.25105.
PubMed Abstract available

CAO J, Wang G, Cheng H, Wei C, et al
Potent anti-leukemia activities of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25108.
PubMed Abstract available

PUNGOLINO E, Rossi G, De Canal G, Trojani A, et al
Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia.
Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25106.
PubMed

CAOCCI G, Mulas O, Annunziata M, Luciano L, et al
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol. 2018 Apr 6. doi: 10.1002/ajh.25102.
PubMed

March 2018

JIN CH, Li Y, Xia J, Li Y, et al
CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
Am J Hematol. 2018 Mar 30. doi: 10.1002/ajh.25099.
PubMed Abstract available

CZYZ A, Labopin M, Giebel S, Socie G, et al
Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Soc
Am J Hematol. 2018 Mar 25. doi: 10.1002/ajh.25091.
PubMed Abstract available

LI Z, Labopin M, Ciceri F, Blaise D, et al
Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study.
Am J Hematol. 2018 Mar 14. doi: 10.1002/ajh.25087.
PubMed Abstract available

OGDEN J, Yui J, Ali W, Mudireddy M, et al
Pre-Anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.
Am J Hematol. 2018 Mar 6. doi: 10.1002/ajh.25083.
PubMed

CANAANI J, Labopin M, Huang XJ, Arcese W, et al
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT.
Am J Hematol. 2018 Mar 2. doi: 10.1002/ajh.25082.
PubMed Abstract available

JABBOUR E, Kantarjian H
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Am J Hematol. 2018;93:442-459.
PubMed Abstract available

February 2018

KHODER A, Al Obaidi M, Babb A, Liu C, et al
Chronic neutrophilic leukemia.
Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25073.
PubMed

WIERZBOWSKA A, Wawrzyniak E, Pluta A, Robak T, et al
Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.
Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25062.
PubMed

OTTONE T, Alfonso V, Iaccarino L, Hasan SK, et al
Longitudinal detection of DNMT3A(R882H) transcripts in patients with acute myeloid leukemia.
Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25061.
PubMed

BORLENGHI E, Pagani C, Zappasodi P, Bernardi M, et al
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
Am J Hematol. 2018;93:E54-E57.
PubMed

GENTILE M, Shanafelt TD, Mauro FR, Laurenti L, et al
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
Am J Hematol. 2018;93:E35-E37.
PubMed

January 2018

HERGOTT CB, Pozdnyakova O
Evans syndrome secondary to undiagnosed chronic lymphocytic leukemia in a patient with unexplained bleeding.
Am J Hematol. 2018 Jan 17. doi: 10.1002/ajh.25039.
PubMed

CASSADAY RD, Stevenson PA, Wood BL, Becker PS, et al
Description and Prognostic Significance of the Kinetics of Minimal Residual Disease Status in Adults with Acute Lymphoblastic Leukemia Treated with HyperCVAD.
Am J Hematol. 2018 Jan 10. doi: 10.1002/ajh.25030.
PubMed Abstract available

ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.
Am J Hematol. 2018;93:47-57.
PubMed Abstract available

BARRETT A, Catherwood M, Thornton P, Murphy P, et al
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy.
Am J Hematol. 2018;93:E16-E17.
PubMed

GUILLERMIN Y, Herbaux C, Subtil F, Aurran-Schleinitz T, et al
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
Am J Hematol. 2018;93:E24-E27.
PubMed

CALDWELL I, Ruskova A, Eaddy N, Bain BJ, et al
Acute leukemic transformation of myelodysplastic syndrome: Is cytochemistry still relevant?
Am J Hematol. 2018;93:148-149.
PubMed

December 2017

ASSI R, Ravandi F
FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.
Am J Hematol. 2017 Dec 29. doi: 10.1002/ajh.25027.
PubMed Abstract available

DECROOCQ J, Itzykson R, Vigouroux S, Michallet M, et al
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cel
Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25004.
PubMed Abstract available

BAIN BJ
Pure erythroid leukemia.
Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25005.
PubMed

DINARDO CD, Rausch CR, Benton C, Kadia T, et al
Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies.
Am J Hematol. 2017 Dec 8. doi: 10.1002/ajh.25000.
PubMed Abstract available

TROUSSARD X, Cornet E
Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
Am J Hematol. 2017;92:1382-1390.
PubMed Abstract available

CHAPIRO E, Lesty C, Gabillaud C, Durot E, et al
"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Am J Hematol. 2017 Dec 1. doi: 10.1002/ajh.24990.
PubMed Abstract available

MOLICA M, Canichella M, Alunni Fegatelli D, Colafigli G, et al
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.
Am J Hematol. 2017;92:E661-E664.
PubMed

KOBAYASHI T, Nannya Y, Ichikawa M, Oritani K, et al
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
Am J Hematol. 2017;92:1324-1332.
PubMed Abstract available

November 2017

JABBOUR E, Dull J, Yilmaz M, Khoury JD, et al
Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression.
Am J Hematol. 2017 Nov 27. doi: 10.1002/ajh.24987.
PubMed Abstract available

RIBES D, El Hachem H, Oberic L, Vergez F, et al
Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
Am J Hematol. 2017 Nov 23. doi: 10.1002/ajh.24984.
PubMed Abstract available

GODET S, Protin C, Dupuis J, Dartigeas C, et al
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO).
Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24981.
PubMed

WALTER RB, Michaelis LC, Othus M, Uy GL, et al
Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia.
Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24980.
PubMed

VENTON G, Courtier F, Charbonnier A, D'Incan E, et al
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
Am J Hematol. 2017 Nov 17. doi: 10.1002/ajh.24973.
PubMed Abstract available

ALTMAN JK, Foran JM, Pratz KW, Trone D, et al
Phase 1 Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Am J Hematol. 2017 Nov 15. doi: 10.1002/ajh.24974.
PubMed Abstract available

DEANGELO DJ, Brunner AM, Werner L, Avigan D, et al
A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia.
Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24968.
PubMed Abstract available

CANAANI J, Savani BN, Labopin M, Huang XJ, et al
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24963.
PubMed Abstract available

SANDMAIER BM, Khaled S, Oran B, Gammon G, et al
Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant.
Am J Hematol. 2017 Nov 1. doi: 10.1002/ajh.24959.
PubMed Abstract available

October 2017

MINETTO P, Guolo F, Clavio M, Kunkl A, et al
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
Am J Hematol. 2017 Oct 28. doi: 10.1002/ajh.24956.
PubMed

COOMBS CC, Mathews SP
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
Am J Hematol. 2017 Oct 20. doi: 10.1002/ajh.24950.
PubMed

ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
PubMed Abstract available

ALHURAIJI A, Kantarjian H, Boddu P, Ravandi F, et al
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24943.
PubMed Abstract available

KHODER A, Al Obaidi M, Wiles N, Nadal-Melsio E, et al
Lymphoplasmacytoid cytology in plasma cell leukemia.
Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24940.
PubMed

TEFFERI A, Hanson CA, Ketterling RP
Revisiting the need for bone marrow examination in chronic myeloid leukemia.
Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24942.
PubMed

PATNAIK MM, Vallapureddy R, Yalniz FF, Hanson CA, et al
Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic and Clinical Distinctions from de novo CMML.
Am J Hematol. 2017 Oct 11. doi: 10.1002/ajh.24939.
PubMed Abstract available

IZZI V, Lakkala J, Devarajan R, Savolainen ER, et al
Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia.
Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24925.
PubMed

LAZAREVIC VL, Labopin M, Wu D, Yakoub-Agha I, et al
Relatively favourable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24928.
PubMed Abstract available

EL FAKIH R, Jabbour E, Ravandi F, Hassanein M, et al
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24926.
PubMed Abstract available

SPERR WR, Herndlhofer S, Gleixner K, Girschikofsky M, et al
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years.
Am J Hematol. 2017;92:E567-E574.
PubMed Abstract available

RASHIDI A, Linden MA, DeFor TE, Warlick E, et al
History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Am J Hematol. 2017;92:1032-1036.
PubMed Abstract available

SHIMONI A, Vago L, Bernardi M, Yerushalmi R, et al
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Am J Hematol. 2017;92:1011-1019.
PubMed Abstract available

MOLOGNI L, Piazza R, Khandelwal P, Pirola A, et al
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
Am J Hematol. 2017;92:E623-E625.
PubMed

JAIN P, Burger JA, Khoury JD
CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
Am J Hematol. 2017;92:1113-1114.
PubMed

September 2017

GAKSCH L, Kashofer K, Heitzer E, Quehenberger F, et al
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
Am J Hematol. 2017 Sep 29. doi: 10.1002/ajh.24922.
PubMed Abstract available

BRECCIA M, Colafigli G, Molica M, Scalzulli E, et al
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
Am J Hematol. 2017 Sep 28. doi: 10.1002/ajh.24916.
PubMed

HAMPEL PJ, Chaffee KG, King RL, Simonetto D, et al
Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings.
Am J Hematol. 2017 Sep 22. doi: 10.1002/ajh.24915.
PubMed Abstract available

CHANG YJ, Zhao XS, Wang Y, Liu YR, et al
Effects of Pre- and Post-transplantation Minimal Residual Disease on Outcomes in Pediatric Patients with Acute Myeloid Leukemia Receiving Human Leukocyte Antigen-matched or Mismatched Related Donor Allografts.
Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24910.
PubMed

GORIN NC, Labopin M, Pabst T, Remenyi P, et al
Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
Am J Hematol. 2017 Sep 11. doi: 10.1002/ajh.24904.
PubMed Abstract available

HALLEK M
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Am J Hematol. 2017;92:946-965.
PubMed Abstract available

PERERA LP, Zhang M, Nakagawa M, Petrus MN, et al
Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
Am J Hematol. 2017;92:892-901.
PubMed Abstract available

BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
A centrocyte blood count of a quarter million.
Am J Hematol. 2017;92:972-973.
PubMed

August 2017

SHI CR, Nambudiri VE
Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Am J Hematol. 2017 Aug 24. doi: 10.1002/ajh.24894.
PubMed

GOLDBERG SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, et al
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Am J Hematol. 2017 Aug 17. doi: 10.1002/ajh.24887.
PubMed Abstract available

COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
A life-threatening ruxolitinib discontinuation syndrome.
Am J Hematol. 2017;92:833-838.
PubMed

YSEBAERT L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, et al
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
Am J Hematol. 2017;92:E166-E168.
PubMed

July 2017

BEGNA K, Al-Kali A, Elliott M, Foran J, et al
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
Am J Hematol. 2017 Jul 21. doi: 10.1002/ajh.24866.
PubMed

BAIN BJ
Pure erythroid leukemia: the need gather data on this condition as defined in the World Health Organisation classification.
Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24863.
PubMed

VALLAPUREDDY R, Lasho TL, Hoversten K, Finke CM, et al
Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance.
Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24861.
PubMed

WANG W, Wang S, Medeiros LJ, Khoury JD, et al
Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia.
Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24862.
PubMed

JAROSOVA M, Hruba M, Oltova A, Plevova K, et al
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24852.
PubMed

KLIL-DRORI AJ, Yin H, Azoulay L, Harnois M, et al
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Am J Hematol. 2017 Jul 3. doi: 10.1002/ajh.24838.
PubMed

RHEE SJ, Lee JW, Yu KS, Hong KT, et al
Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Am J Hematol. 2017;92:607-613.
PubMed Abstract available

June 2017

JAIN P, Kantarjian H, Jain N, Short NJ, et al
Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
PubMed

LEVIN A, Kleman A, Rein L, Tarima S, et al
Early Mortality in Patients with Acute Myelogenous Leukemia Treated in Teaching versus Non-teaching Hospitals: A Large Database Analysis.
Am J Hematol. 2017 Jun 20. doi: 10.1002/ajh.24825.
PubMed

EDER S, Canaani J, Beohou E, Labopin M, et al
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Socie
Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24823.
PubMed Abstract available

TERRY CM, Shallis RM, Estey E, Lim SH, et al
Day 14 bone marrow examination in the management of acute myeloid leukemia.
Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24818.
PubMed Abstract available

BAZIN J, Karnik L, Tudor-Williams G, Kelly AM, et al
Juvenile myelomonocytic leukemia in an infant with congenital HIV and CMV infection.
Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24815.
PubMed

CROMBIE J, Davids MS
IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia.
Am J Hematol. 2017 Jun 7. doi: 10.1002/ajh.24808.
PubMed Abstract available

SALEM A, Loghavi S, Tang G, Huh YO, et al
Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Am J Hematol. 2017;92:520-528.
PubMed Abstract available

MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
Am J Hematol. 2017;92:E91-E93.
PubMed

DE ROCCO D, Melazzini F, Marconi C, Pecci A, et al
Mutations of RUNX1 in families with inherited thrombocytopenia.
Am J Hematol. 2017;92:E86-E88.
PubMed

May 2017

RASHIDI A, Ali AM, Vij KR, Shanley R, et al
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Am J Hematol. 2017 May 31. doi: 10.1002/ajh.24804.
PubMed

JABBOUR E, Daver NG, Short NJ, Huang X, et al
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
Am J Hematol. 2017 May 27. doi: 10.1002/ajh.24799.
PubMed Abstract available

KONDO T, Nagamura-Inoue T, Tojo A, Nagamura F, et al
Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Am J Hematol. 2017 May 20. doi: 10.1002/ajh.24793.
PubMed Abstract available

ALDOSS I, Song J, Stiller T, Nguyen T, et al
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24783.
PubMed Abstract available

RAGON BK, Daver N, Garcia-Manero G, Ravandi F, et al
Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia.
Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24782.
PubMed Abstract available

GONCALVES MV, Rodrigues CA, Metze IGHL, Lacerda MP, et al
Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases.
Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24779.
PubMed

NANAH R, McCullough K, Hogan W, Begna K, et al
Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience.
Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24780.
PubMed Abstract available

CASTAGNETTI F, Gugliotta G, Breccia M, Iurlo A, et al
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Am J Hematol. 2017 May 2. doi: 10.1002/ajh.24774.
PubMed Abstract available

Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
Am J Hematol. 2017;92:E85.
PubMed

April 2017

CANAANI J, Savani BN, Labopin M, Michallet M, et al
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT.
Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24771.
PubMed Abstract available

BHATT VR, Shostrom V, Giri S, Gundabolu K, et al
Early Mortality and Overall Survival of Acute Myeloid Leukemia Based on Facility Type.
Am J Hematol. 2017 Apr 24. doi: 10.1002/ajh.24767.
PubMed Abstract available

LARSEN JT, Shanafelt TD, Leis JF, LaPlant B, et al
Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study.
Am J Hematol. 2017 Apr 12. doi: 10.1002/ajh.24762.
PubMed Abstract available

BAPTISTA MJ, Granada I, Morgades M, Calasanz MJ, et al
Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance.
Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24754.
PubMed

REDA G, Cassin R, Fattizzo B, Giannarelli D, et al
Chronic lymphocytic leukemia (CLL) and prognostic models: A bridge between clinical and biological markers.
Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24755.
PubMed

SACHA T, Gora-Tybor J, Szarejko M, Bober G, et al
A multicenter prospective study on efficacy and safety of imatinib generics; a report from Polish Adult Leukemia Group imatinib generics registry.
Am J Hematol. 2017 Apr 4. doi: 10.1002/ajh.24748.
PubMed Abstract available

YU Y, Zhang T, Wang Q, Wu D, et al
Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
Am J Hematol. 2017;92:E55-E57.
PubMed

PEMMARAJU N, Jain P, Medeiros LJ, Jorgenson JL, et al
PET-positive lymphadenopathy in CLL-Not always Richter transformation.
Am J Hematol. 2017;92:405-406.
PubMed

March 2017

WEINBERG OK, Gibson CJ, Blonquist TM, Neuberg D, et al
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification.
Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24739.
PubMed

CANAANI J, Labopin M, Socie G, Nihtinen A, et al
Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.
Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24737.
PubMed Abstract available

KANTARJIAN HM, Schuster MW, Jain N, Advani A, et al
A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia.
Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24736.
PubMed Abstract available

ALFONSO A, Montalban-Bravo G, Takahashi K, Jabbour EJ, et al
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24735.
PubMed Abstract available

KANDARPA M, Wu YM, Robinson D, Burke PW, et al
Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.
Am J Hematol. 2017 Mar 23. doi: 10.1002/ajh.24728.
PubMed Abstract available

GRIFFIN PT, Komrokji RS, Sweet K, Al Ali NH, et al
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Am J Hematol. 2017;92:232-237.
PubMed Abstract available

February 2017

NAKASONE H, Fuji S, Yakushijin K, Onizuka M, et al
Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.
Am J Hematol. 2017;92:171-178.
PubMed Abstract available

DINARDO CD, Luskin MR, Carroll M, Smith C, et al
Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
Am J Hematol. 2017;92:E14-E15.
PubMed

January 2017

TEFFERI A, Barbui T
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Am J Hematol. 2017;92:94-108.
PubMed Abstract available

RAGON BK, Kantarjian H, Jabbour E, Ravandi F, et al
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Am J Hematol. 2017;92:7-11.
PubMed Abstract available

JAIN P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, et al
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
Am J Hematol. 2017;92:E3-E4.
PubMed

JAIN P, Nagarajan P, Prayag P, Benton CB, et al
Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.
Am J Hematol. 2017;92:119-120.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: